For example, the Galectin-1 inhibitor showed significant anti-cancer effects both in vitro and in vivo in thyroid cancer lines expressing Gal-1 (Gheysen et al., 2021), and the Galectin-1 inhibitor had been used to treat B-cell precursor acute lymphoblastic leukemia (Paz et al., 2018) and head and neck squamous cell carcinomas (Koonce et al., 2017). The gene discussed is LGALS1; the disease is precursor B-cell acute lymphoblastic leukemia.